Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis

被引：1
|
作者：
Waks, A. G. [1 ]
Gharaibeh, M. [2 ]
Sjekloca, N. [3 ]
Poluparthi, N. [2 ]
Shah, A. [2 ]
Bergamaco, E. [4 ]
MacCannell, T. [2 ]
Leung, G. [5 ]
Ntalla, I. [6 ]
Oko-osi, H. [2 ]
Tolaney, S. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Gilead Sci Inc, Dept Hlth Econ & Outcomes Res, Foster City, CA USA
[3] Gilead Sci Europe Ltd, Dept Med Affairs, Stockley Pk, CA USA
[4] Gilead Sci Inc, Dept Med Affairs, Foster City, CA USA
[5] Gilead Sci Inc, Dept Real World Evidence, Foster City, CA USA
[6] Gilead Sci Europe Ltd, Dept Real World Evidence, Stockley Pk, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253P
引用
收藏
页码：S653 / S653
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [2] Real-world clinical outcomes in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Tolaney, Sara M.
    Punie, Kevin
    Kurian, Allison W.
    Ntalla, Ioanna
    Verret, Wendy
    Sadetsky, Natalia
    Sjekloca, Nikoleta
    Stokes, Michael
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [4] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [5] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Unmet clinical need in patients with pre-treated hormone receptor- positive/HER2-negative (HR+/HER2-) metastatic breast cancer in routine care: a targeted literature review
    Spring, Laura
    Collin, Simon M.
    Dhillon, Inderjit K.
    Long, Grainne
    Bertranou, Evelina
    Jhaveri, Komal
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (09)
  • [7] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [8] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [9] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [10] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
12345